In English | En español
Questions About Cancer? 1-800-4-CANCER
  • Posted: 12/12/2013

Find News Releases

Search For:
Between these dates:

Page Options

  • Print This Page
  • Email This Document
NCI Cancer Center News

Study identifies highly effective treatment option for patients with HER2-positive breast cancer

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study (led by researchers from the UCLA Jonsson Comprehensive Cancer Center) presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

Click here to read full press release.

###

NCI comprehensive cancer centers logoAmong the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.